Tech Company Financing Transactions
X4 Pharmaceuticals Funding Round
X4 Pharmaceuticals, based in Cambridge, secured $115 million from Hercules Capital.
Transaction Overview
Company Name
Announced On
8/3/2023
Transaction Type
Debt
Amount
$115,000,000
Round
Undisclosed
Investors
Hercules Capital (Lead Investor)
Proceeds Purpose
This expanded loan facility creates significant financial flexibility for X4 as we continue preparations for the potential commercial launch of mavorixafor in individuals with WHIM syndrome and continue to advance mavorixafor for certain chronic neutropenic disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
955 Massachusetts Ave. 4th Floor 140
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-Cells to track and destroy cancer cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paula Ragan
Chief Financial Officer
Adam Mostafa
Chief Medical Officer
Kenneth Gorelick
VP - Human Resources
Ronny Mosston
VP - Operations
Mary DiBiase
VP - Operations
Celeste DiJohnson
VP - Regulatory Affairs
Tarek Ebrahim
Browse more venture capital transactions:
Prev: 8/3/2023: DBtune venture capital transaction
Next: 8/3/2023: Tenstorrent venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs